AMAG Pharmaceuticals, Inc. to Present at Canaccord Genuity 30th Annual Global Growth Conference

LEXINGTON, Mass.--(BUSINESS WIRE)-- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that management will present an overview of the company at the Canaccord Genuity 30th Annual Global Growth Conference on August 10, 2010 at 9:00 a.m. ET. The conference is being held August 10-12, 2010 in Boston, MA.

A live webcast of the presentation will be accessible through the Investors section of the company’s website at www.amagpharma.com. Following the conference, the webcast will be archived on the AMAG Pharmaceuticals, Inc. website for approximately two weeks.

About AMAG Pharmaceuticals, Inc.

AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes its proprietary technology for the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease. AMAG manufactures and sells two commercial products, Feraheme® (ferumoxytol) Injection for intravenous (IV) use and GastroMARK®, an oral contrast agent used in magnetic resonance imaging. For additional company information, please visit www.amagpharma.com.

Feraheme is a registered trademark of AMAG Pharmaceuticals, Inc.



CONTACT:

AMAG Pharmaceuticals
Carol Miceli, 617-498-3361

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical  Other Health  Professional Services  Finance  Research  Science

MEDIA:

Suggested Articles

In the first half of 2020, the regenerative medicine sector raised $10.7 billion, more than the total it raised in 2019.

The trial linked RG6346 to reductions in hepatitis B surface antigen that suggest the RNAi therapy can hold its own against drugs from J&J and Vir.

Creating new, successful central nervous system drugs is tough, and Lundbeck knows this better than most after canning an internal CNS effort.